James L Mullins

US Patent:

6887707, May 3, 2005

Filed:

Mar 10, 2000

Appl. No.:

09/522373

Inventors:

Lawrence A. Loeb - Bellevue WA, US
James I. Mullins - Seattle WA, US

Assignee:

University of Washington - Seattle WA

International Classification:

C12N015/01
C12N007/00
C12P019/34
C07H021/02

US Classification:

435442, 435 913, 435 9132, 4352351, 435236, 435325, 435366, 4353723, 435440, 435441, 536 221, 536 231

Abstract:

The present invention is directed to the identification and use of ribonucleoside analogs to induce the mutation of an RNA virus, including BVDV, HIV and HCV, or a virus which otherwise replicates through an RNA intermediate. The increase in the mutation rate of the virus results in reduced viability of progeny generations of the virus, thereby inhibiting viral replication. In addition to these methods and related compositions, the invention provides methods and combinatorial chemistry libraries for screening ribonucleoside analogs for mutagenic potential.

US Patent:

7655774, Feb 2, 2010

Filed:

Feb 17, 2004

Appl. No.:

10/780507

Inventors:

James I. Mullins - Seattle WA, US
Allen G. Rodrigo - Auckland, NZ
Gerald H. Learn - Kingston WA, US
Fusheng Li - Seattle WA, US
David C. Nickle - Seattle WA, US
Mark A. Jensen - Snohomish WA, US

Assignee:

University of Washington - Seattle WA

International Classification:

C07H 21/02
C12N 15/00
C12N 1/20

US Classification:

536 231, 4353201, 4352523

Abstract:

The present invention is directed to ancestral and COT nucleic acid and amino acid sequences, methods for producing such sequences and uses thereof, including prophylactic and diagnostic uses.

US Patent:

20040115621, Jun 17, 2004

Filed:

May 19, 2003

Appl. No.:

10/441926

Inventors:

Allen Rodrigo - , US
Howard Ross - , US
James Mullins - Seattle WA, US

International Classification:

C12Q001/70
C07H021/04
C07K014/155
C07H021/02

US Classification:

435/005000, 435/069100, 435/320100, 435/325000, 435/456000, 530/350000, 536/023720

Abstract:

The present invention is directed to ancestral HIV and FIV nucleic acid and amino acid sequences, methods for producing such sequences and uses thereof, including prophylactic and diagnostic uses.

US Patent:

20040116684, Jun 17, 2004

Filed:

May 19, 2003

Appl. No.:

10/441949

Inventors:

Allen Rodrigo - , US
Howard Ross - , US
James Mullins - Seattle WA, US

International Classification:

C07H021/04
C12N007/00

US Classification:

536/023720, 435/235100

Abstract:

The present invention is directed to ancestral viral nucleic acid and amino acid sequences, methods for producing such sequences and uses thereof, including prophylactic and diagnostic uses.

US Patent:

20050187180, Aug 25, 2005

Filed:

Apr 4, 2005

Appl. No.:

11/098796

Inventors:

Lawrence Loeb - Bellevue WA, US
James Mullins - Seattle WA, US

Assignee:

University of Washington - Seattle WA

International Classification:

A61K048/00
C12N015/86
C12N007/00

US Classification:

514044000, 435235100, 435456000

Abstract:

The present invention is directed to the identification and use of ribonucleoside analogs to induce the mutation of an RNA virus, including BVDV, HIV and HCV, or a virus which otherwise replicates through an RNA intermediate. The increase in the mutation rate of the virus results in reduced viability of progeny generations of the virus, thereby inhibiting viral replication. In addition to these methods and related compositions, the invention provides methods and combinatorial chemistry libraries for screening ribonucleoside analogs for mutagenic potential.

US Patent:

20070009551, Jan 11, 2007

Filed:

Feb 16, 2001

Appl. No.:

10/204204

Inventors:

James Mullins - Seattle WA, US
Allen Rodrigo - Auckland, NZ
Gerald Learn - Kingston WA, US
Fusheng Li - Seattle WA, US

International Classification:

C12Q 1/70
C07H 21/04
A61K 39/21
C07K 14/16
C07K 16/10
C12N 15/867
C07H 21/02

US Classification:

424208100, 435005000, 435069300, 435456000, 435325000, 530350000, 536023720, 530388300

Abstract:

The present invention is directed to ancestral HIV nucleic acid and amino acid sequences, methods for producing such sequences and uses thereof, including prophylactic and diagnostic uses.

US Patent:

20090092628, Apr 9, 2009

Filed:

Mar 2, 2007

Appl. No.:

11/713474

Inventors:

James Mullins - Seattle WA, US
David Nickle - Seattle WA, US
Morgane Rolland - Seattle MA, US

International Classification:

A61K 39/00
G06F 19/00

US Classification:

4241881, 702 20

Abstract:

Embodiments of the present invention include conserved-element vaccines and methods for designing and producing conserved-element vaccines. A conserved-element vaccine (“CEVac”) is a recombinant and/or synthetic vaccine that incorporates only highly conserved epitopes from an observed set of pathogen variants. The conserved epitopes are identified computationally by aligning biopolymer sequences, such as concatenated polypeptide sequences that together represent a pathogen proteome, corresponding to an observed set of pathogen variants, and computationally selecting conserved subsequences according to a number of subsequence-selection criteria. These subsequence-selection criteria may include a minimum conserved-subsequence length, a threshold frequency of occurrence of a particular monomer at each conserved, single-monomer position within a conserved subsequence, a threshold combined occurrence for a set of allowable variant monomers at a particular conserved, variable position within a conserved subsequence, and a maximum number of variable positions within a subsequence. A set of conserved subsequences identified according to the subsequence-selection criteria are then filtered to remove subsequences identical to, or too similar to, naturally-occurring host subsequences, and are then assembled into expression vectors for incorporation into microbial hosts for biosynthesis of a recombinant CEVac or assembled into one or more synthetic constructs for a synthetic CEVac.

US Patent:

20110269937, Nov 3, 2011

Filed:

Apr 29, 2011

Appl. No.:

13/097592

Inventors:

James Mullins - Seattle WA, US
David Nickle - Seattle WA, US
Morgane Rolland - Seattle WA, US

Assignee:

higher education - Seattle WA

International Classification:

C07K 7/08
C07K 7/06
G06N 5/00
C07H 21/04

US Classification:

530326, 530327, 536 2372, 530328, 706 46

Abstract:

Embodiments of the present invention include conserved-element vaccines and methods for designing and producing conserved-element vaccines. A conserved-element vaccine (“CEVac”) is a recombinant and/or synthetic vaccine that incorporates only highly conserved epitopes from an observed set of pathogen variants. The conserved epitopes are identified computationally by aligning biopolymer sequences, such as concatenated polypeptide sequences that together represent a pathogen proteome, corresponding to an observed set of pathogen variants, and computationally selecting conserved subsequences according to a number of subsequence-selection criteria. These subsequence-selection criteria may include a minimum conserved-subsequence length, a threshold frequency of occurrence of a particular monomer at each conserved, single-monomer position within a conserved subsequence, a threshold combined occurrence for a set of allowable variant monomers at a particular conserved, variable position within a conserved subsequence, and a maximum number of variable positions within a subsequence. A set of conserved subsequences identified according to the subsequence-selection criteria are then filtered to remove subsequences identical to, or too similar to, naturally-occurring host subsequences, and are then assembled into expression vectors for incorporation into microbial hosts for biosynthesis of a recombinant CEVac or assembled into one or more synthetic constructs for a synthetic CEVac.